Pharmaniaga reports narrower loss for FY23 on restructuring initiatives


KUALA LUMPUR: Pharmaniaga Bhd’s net loss for the financial year ended Dec 31, 2023 (FY2023) narrowed to RM77.45 million from RM629.92 million in FY2022.

Revenue dropped to RM3.40 billion from RM3.48 billion, representing a 2.2 per cent decrease, mainly due to the reduction in revenue from its concession business as a result of a lower budget allocation.

For the fourth quarter (4Q), its net loss shrank to RM32.72 million from a loss of RM644.39 million, while revenue slid to RM789.81 million from RM862.72 million in the previous year.

The pharmaceutical group sees a promising outlook this year following a comprehensive restructuring of business operations and the implementation of numerous initiatives aimed at revitalising the group in 2023.

"(The better performance) was anchored by a coherent strategic blueprint, articulated through five principal pillars - fortifying our engagement in the public sector, enhancing our biopharmaceutical endeavours, streamlining costs, expanding into private markets, and transforming our operations in Indonesia.

"These efforts are intended to promote long-term growth and spark opportunities for value creation,” it said in a stock exchange filing.

Pharmaniaga revealed that it is finalising an acquisition vaccine development grant from the Ministry of Science, Technology, and Innovation (MOSTI).

"This grant not only underscores the government's support for our endeavours but will also position the group at the forefront of healthcare innovation, particularly in the critical area of vaccine development,” it said.

The group said that it will continue to navigate through several challenges that impact its financial and operational performance.

"Factors such as global fluctuations in the US dollar, increased finance costs due to the rising overnight policy rate (OPR), elevated electricity tariffs, and higher labour costs following amendments in the Employment Act collectively exert pressure on our margins and overall profitability.

"In addressing these challenges, the group remains dedicated to the initiatives on improving profit margin and cost optimisation to ensure resilience and sustainability,” it said. - Bernama

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Pharmaniaga , results , FY2023

Next In Business News

Bank Negara continues to monitor domestic inflation, growth outlook for sustainable growth
Proton e.MAS 7 production to be boosted amid strong demand
Taghill bags RM58mil building job
YNH sells Aeon Manjung to Sunway REIT for RM138mil
Anwar meets six MNCs including Google, Nestle on the sidelines of WEF 2025
Maxland to diversify into automotive, utility infrastructures and services business
MAHB records 96.1% recovery rate to 135 million passengers in 2024
Ringgit ends higher vs US dollar after Trump's inauguration speech
Keyfield completes solar PV system on work barge, enters Malaysia Book of Records
Pertama Digital appoints Lim Nasrul Halim as its CEO designate

Others Also Read